Skip to main content
. 2001 Feb;158(2):537–542. doi: 10.1016/s0002-9440(10)63995-8

Figure 2.

Figure 2.

A: The tumors prepared from HCT116 cells (which are known to have a truncating mutation of TGFBR2 but are DPC4+/+) have both nuclear (arrow) and cytoplasmic labeling for Dpc4. Immunohistochemistry using anti-Dpc4 antibody, counterstained with hematoxylin. B: A xenograft prepared from cell line 5-60 cells (lacking intact TGFBR2 but DPC4+/−) has both nuclear (arrow) and cytoplasmic labeling with the Dpc4 antibody. Immunohistochemistry using anti-Dpc4 antibody, counterstained with hematoxylin. C: Xenografted tumor prepared from cell line 5-18 cells (lacking intact TGFBR2 and DPC4−/−) showed neither cytoplasmic nor nuclear labeling with the anti-Dpc4 antibody. The labeled cells in this photograph are ingrown stromal cells from the host animal; the large tumor cells (arrow) are unlabeled. Immunohistochemistry using anti-Dpc4 antibody, counterstained with hematoxylin.